Evidence map›Paper›PMID 26604846›Full record

ArticleRisk management and healthcare policy2015

Economic burden of Clostridium difficile in five hospitals of the Florence health care system in Italy.

Anna Poli, Sergio Di Matteo, Giacomo M Bruno, Enrica Fornai, Maria Chiara Valentino, Giorgio L Colombo

Open access · goldAbstract read
In one paragraph

Article in Risk management and healthcare policy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Economic Burden of Clostridioides difficile Infection in European Countries.Advances in experimental medicine and biology · 2024
    Article
  2. Article
  3. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anna PoliVigilanza e Controllo Infezioni Correlate all'Assistenza, Ospedale Piero Palagi, Azienda Sanitaria di Firenze, Firenze, Italy.
Sergio Di MatteoSAVE Studi - Health Economics and Outcomes Research, Milan, Italy.
Giacomo M BrunoSAVE Studi - Health Economics and Outcomes Research, Milan, Italy.
Enrica FornaiVigilanza e Controllo Infezioni Correlate all'Assistenza, Ospedale Piero Palagi, Azienda Sanitaria di Firenze, Firenze, Italy.
Maria Chiara ValentinoSAVE Studi - Health Economics and Outcomes Research, Milan, Italy.
Giorgio L ColomboSAVE Studi - Health Economics and Outcomes Research, Milan, Italy ; Department of Drug Sciences, University of Pavia, Pavia, Italy.
Center for Outcomes Research and Clinical Epidemiology · ITAzienda Sanitaria di Firenze · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite the awareness about the increasing rates of Clostridium difficile infection (CDI) and the economic burden arising from its management (prolonged hospitalization, laboratory tests, visits, surgical treatment, environmental sanitation), few studies are available in Italy on the economic costs directly attributable to the CDI. The Florence health care system has designed a study with the aim of describing the costs attributable to the CDI and defines the incremental economic burden associated with the management of this complication.

methodsWe conducted a retrospective study in five hospitals of the Florence health care system. The enrolled population included all patients who were hospitalized during the year 2013 with a diagnosis of CDI. Of the 187 total cases reported in 2013, 69 patients were enrolled, for whom the main cause of hospitalization was directly attributable to CDI.

resultsWe enrolled 69 patients (19 males and 50 females), with a mean age of 82.16 years (minimum 46 to maximum 98). The total number of hospitalization days observed was 886 (12.8 per patient on average). The data from this study show that the mean total incremental cost for a patient with CDI was €3,270.52 per year. The hospital stay length is the most significant cost parameter, having the largest influence on the overall costs, with an impact of 87% on the total cost. The results confirm the costs for the management of CDI in five hospitals of the Florence health care system are in line with data from the international literature.

conclusionThe economic impact of CDI is most evident in the extension of the duration of hospitalization and emergency recurrences requiring new therapeutic options with the need to develop and implement new diagnostic and therapeutic algorithms in clinical practice.

Indexed as

burden of diseasecost analysiscost of illnesspharmacoeconomics

Identifiers

PMID26604846
PMCPMC4655953
OpenAlexW2173447410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.